Please assess the completion status of the following clinical trial:

Trial Title: The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical history of perennial allergic rhinitis and a positive skin prick test to dust mite, cockroach, mold, or cat or dog antigens.~* Willingness of the subject to participate in and complete the study, and the ability to understand the purpose of the trial.~Exclusion Criteria:~* Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.~* Women of childbearing potential who are pregnant, trying to become pregnant or nursing a child.~* Subjects treated with systemic steroids during the previous 30 days.~* Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom or Opticrom during the previous 15 days.~* Subjects treated with oral antihistamines/decongestants during the previous seven days.~* Subjects treated with topical (intranasal or intraocular) antihistamines/decongestants during the previous 3 days.~* Subjects treated with immunotherapy who are escalating their dose.~* Subjects on chronic anti-asthma medications.~* Subjects with polyps in the nose or a significantly displaced septum.~* Subjects who have incurred an upper respiratory tract infection within 14 days of the start of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Fluticasone propionate + Placebo (Type: PLACEBO_COMPARATOR): Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily)~Placebo - 10 mg po daily for 2 weeks
- Fluticasone propionate + Montelukast (Type: ACTIVE_COMPARATOR): Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily)~Montelukast - 10 mg po daily for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).